一次情報の記録
Vistagen held a Type C meeting with FDA on potential Phase 3 development of fasedienol (intranasal pherine) for social anxiety disorder using LSAS as primary endpoint. FDA provided feedback on interim assessments of acute vs longer-term effects and recommended focusing on overall (not acute-only) treatment in the general SAD population. Vistagen will incorporate eDiary and survey interim assessments and submit a revised protocol.
EX-99.1 2 vtgnex99111092026.htm EX-99.1 文書 EXHIBIT 99.1 Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder Constructive feedback from FDA clarifies potential Phase 3 development path forward SOUTH SAN FRANCISCO, Calif. (NEWSWIRE) November 9, 2026, Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced a regulatory update from its recent, productive Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss potential registrational paths forward for the development of its lead product candidate, fasedienol, in social anxiety disorder (SAD). The FDA shared constructive feedb